Mineralstoffpräparate und Osteoporosemittel Ulrich Schwabe und Reinhard Ziegler

American Medical Association (1986): Agents affecting calcium metabolism. In: Drug Evaluations, 6th ed, Saunders Company, Philadelphia,pp. 827–839, 885–902.Google Scholar

Arzneimittelkommission der Deutschen Ärzteschaft (2003): Empfehlungen zur Therapie und Prophylaxe der Osteoporose. Arzneiverordnung in der Praxis (Sonderheft 34S).Google Scholar

Bone HG, Hosking D, Devogelaer D et al (2004): Ten years’ experience with alendronate for osteoporosis in postmenopausal women. N Engl J Med 350: 1189–1199.CrossRefPubMedGoogle Scholar

Crowther CA, Hiller JE, Doyle LW, Haslam RR (2003): Effect of magnesium sulfate given for neuroprotection before preterm birth. JAMA 290: 2669–2676.CrossRefPubMedGoogle Scholar

Dawson-Hughes B, Harris SS, Krall EA, Dallal GE (1997): Effect of calcium and vitamin D supplementation on bone density in men and women 65 years of age or older. N Engl J Med 337: 670–676.CrossRefPubMedGoogle Scholar

Djavan B, Thompson I, Michel MS, Waldert M, Seitz C (2004): Chemoprävention des Prostatakarzinoms. Urologe A 43: 557–561.CrossRefPubMedGoogle Scholar

Duffield-Lillico AJ, Slate EH, Reid ME, Turnbull BW, Wilkins PA, Combs GF Jr, Park HK, Gross EG, Graham GF, Stratton MS, Marshall JR, Clark LC; Nutritional Prevention of Cancer Study Group (2003): Selenium supplementation and secondary prevention of nonmelanoma skin cancer in a randomized trial. J Natl Cancer Inst 95: 1477–1481.PubMedGoogle Scholar

Fleisch H (2000): Bisphosphonates in bone disease. From the laboratory to the patient. 4^th ed, Academic Press, San Diego etc., pp. 1–212.Google Scholar

Galloe AM, Rasmussen HS, Jorgensen LN, Aurup P, Balslov S et al (1993): Influence of oral magnesium supplementation on cardiac events among survivors of an acute myocardial infarction. Brit Med J 307: 585–587.PubMedGoogle Scholar

Guerrero-Romero F, Tamez-Perez HE, González-González E et al (2004): Oral magnesium supplementation improves insulin sensitivity in non-diabetic subjects with insulin resistance. A double-blind placebo-controlled randomized trial. Diabetes Metab 30: 253–258.PubMedGoogle Scholar

Haguenauer D, Welch V, Shea B, Tugwell P, Wells G (2000): Fluoride for treating post-menopausal osteoporosis. Cochrane Database Syst Rev. 2000; (4):CD002825.Google Scholar

Hersh AL, Stefanick ML, Stafford RS (2004): National use of postmenopausal hormone therapy. Annual trends and response to recent evidence. JAMA 291: 47–53.CrossRefPubMedGoogle Scholar

ISIS-4 Collaborative Group (1995): ISIS-4: a randomised Arctoriol trial assessing early oral Captopril, oral mononitrate and intravenous magnesium sulphate in 58050 patients with suspected acute myocardial infarction. Lancet 345: 669–685.Google Scholar

Kuhlmann U, Siegenthaler W, Siegenthaler G (1987): Wasser-und Elektrolythaushalt. In: Siegenthaler W. (Hrsg): Klinische Pathophysiologie. Georg Thieme Verlag, Stuttgart New York, S. 209–237.Google Scholar

Lacour M, Zunder T, Restle A, Schwarzer G (2004): No evidence for an impact of selenium supplementation on environment associated health disorders — a systematic review. Int J Hyg Environ Health 207: 1–13.CrossRefPubMedGoogle Scholar

Manz M, Mletzko R, Jung W, Lüderitz B (1990): Behandlung von Herzrhythmusstörungen mit Magnesium. Dtsch Med Wschr 115: 386–390.PubMedGoogle Scholar

Meunier PJ, Roux C, Seeman E et al (2004): The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 350: 459–486.CrossRefPubMedGoogle Scholar

Meyer P, Boettger MB (2001): Familial hypomagnesaemia with second hypocalcemia: A new case that indicates autosomal recessive inheritance. J Inherit Metab Dis 24: 875–876.CrossRefPubMedGoogle Scholar

Miller PD, Watts NB, Licata AA et al (1997): Cyclical etidronate in treatment of postmenopausal osteoporosis. Am J Med 103: 468–476.CrossRefPubMedGoogle Scholar

Neer RM, Arnaud CD, Zanchetta JR, Prince R, Gaich GA, Reginster JY et al (2001): Effect of parathyroid hormone (1–34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 344: 1434–1441.CrossRefPubMedGoogle Scholar

NIH Consensus Conference (1994): Optimal calcium intake. JAMA 272: 1942–1948.Google Scholar

Riggs BL, O’Fallon WM, Lane A, Hodgson SF, Wahner HW et al (1994): Clinical trial of fluoride therapy in postmenopausal osteoporotic women: Extended observations and additional analysis. J Bone Miner Res 9: 265–275.PubMedGoogle Scholar

Shiga T, Wajima Z, Inoue T, Ogawa R (2004): Magnesium prophylaxis for arrhythmias after cardiac surgery: a meta-analysis of randomized controlled trials. Am J Med 117: 325–333.CrossRefPubMedGoogle Scholar

Wüster C, Ziegler R (1993): Fluorid-Therapie der Osteoporose: „Auf die Dosis kommt es an“. Dtsch Ärztebl 90: B-41–42.Google Scholar

Zehender M, Meinertz T, Faber T, Caspary A, Jeron A et al (1997): Antiarrhythmic effects of increasing the daily intake of magnesium and potassium in patients with frequent ventricular arrhythmias. J Am Coll Cardiol 29: 1028–1034.PubMedGoogle Scholar

Ziegler R (2002): Osteoporose: aktuelle Diagnostik und Therapie. Orthopädische Praxis 38: 570–577.Google Scholar